Anlon Healthcare Limited – Investor Presentation Summary
Key Operational Highlights
- Manufacturing capacity utilization: 62.37%
- 65 commercialized products, 28 in pilot stage, and 49 under lab testing
- Served 125 customers to date (directly and indirectly)
- Two dedicated manufacturing blocks for APIs & Intermediates
- Glass-lined and SS reactors with scale-up capability (20L–200L assemblies)
- Strategic location in Rajkot with NH-27 connectivity
Key drivers of operational performance: Capacity expansion through acquisitions (Apiqo and Bizotic), strong product portfolio diversification, and global regulatory approvals.
Segment-wise Performance
Not Specified
Financial Highlights
Revenue: ₹171.97 crore (FY26)
EBITDA: ₹47.77 crore (FY26)
PAT: ₹29.09 crore (FY26)
EPS: ₹6.11 (FY26)
Margins: EBITDA Margin 27.74%, PAT Margin 16.89%
YoY comparison:
- Revenue growth from ₹120.29 crore (FY25) to ₹171.97 crore (FY26)
- EBITDA growth from ₹32.38 crore (FY25) to ₹47.77 crore (FY26)
- PAT growth from ₹20.52 crore (FY25) to ₹29.09 crore (FY26)
Q4 FY26 Performance:
- Revenue: ₹50.89 crore
- EBITDA: ₹15.31 crore (30.07% margin)
- PAT: ₹11.07 crore (21.75% margin)
- EPS: ₹2.33
Drivers of financial performance: Higher revenue growth, operational efficiencies, and acquisition benefits.
Comparison to market estimates: Not Specified
Key Risks: Not explicitly disclosed
Geographical Revenue Split
Not Specified
Balance Sheet Snapshot
Net Worth: ₹254.79 crore (FY26)
Long-Term Borrowings: ₹6.09 crore (FY26)
Short-Term Borrowings: ₹37.56 crore (FY26)
Trade Payables: ₹42.19 crore (FY26)
Fixed Assets: ₹57.76 crore (FY26)
Inventories: ₹113.16 crore (FY26)
Trade Receivables: ₹103.68 crore (FY26)
Cash & Bank Balance: ₹4.37 crore (FY26)
Financial Health Insights: Improved net worth position, reduced long-term borrowings, strong asset base growth.
Capex & Cash Flow Health
Capital Expenditure: Not Specified
Free Cash Flow: Not Specified
Operating Cash Flow: Not Specified
Net Debt Movement: Not Specified
Investment Rationale: Focus on capacity expansion through acquisitions, technology upgrades, and backward integration.
Strategic & R&D Initiatives
Investments in Innovation: 4 in-house R&D centers with 11 fume cupboards, dedicated R&D team, end-to-end CDMO capability
Expected impact on growth: 7 new APIs planned for launch in FY 2026-27 across additional therapeutic categories
Strategic Rationale: Expanding into high-growth markets, reducing operational costs through backward integration, diversifying into Industrial & Fine Chemicals
Industry Trends & Business Environment
Macro/Industry Trends: Global pharmaceutical market projected to grow from USD 1.99 trillion in 2025 to USD 4.03 trillion by 2034 (8.19% CAGR); Global APIs market expected to grow from USD 231.95 billion by 2025 to USD 447.40 billion by 2035 (6.79% CAGR); Indian APIs market expected to reach USD 39.20 billion by 2033 (8.10% CAGR)
Impact on Company: Higher volume demand from global formulators, increased off-take of KSMs & intermediates, long-term outsourcing by innovators
Management Commentary & Growth Outlook
Strategic Outlook: Company poised to deliver ~30% revenue CAGR over the next three years, supported by acquisitions, new launches, and capacity expansion
FY Guidance: Sustainable EBITDA margin of 25-30%; ~30% revenue CAGR over next 3 years
Market Share Targets: Not Specified
Risks and Opportunities: Not explicitly highlighted
Regulatory Approvals & Compliance
- Received CEP Approval from EDQM (Europe) for Ketoprofen API
- Received approval from Brazilian Health Regulatory Agency (ANVISA) for Loxoprofen Sodium Dihydrate
- Received approval from National Medical Products Administration, China (NMPA) for Loxoprofen Sodium Dihydrate
- 21 DMFs filed with regulators across major international markets
- DMF submissions in progress for Ketoprofen in USA and Dexketoprofen Trometamol in key European jurisdictions
- WHO-GMP certification for manufacturing facility
- ISO 9001:2015 Certification
- GMP certification from FDCA, Gujarat
- Foreign Manufacturer Accreditation from PMDA, Japan
Acquisition Details
Bizotic Lifescience Pvt. Ltd. Acquisition:
- Stake: 56.67%
- Consideration: ₹3.79 crore (cash)
- Shares: 25.50 lakh
- Price: ₹14.89 per share
- Status: SPA executed; completion expected within ~3 months
Apiqo Organics Pvt. Ltd. Acquisition:
- Stake: 67.48%
- Consideration: ₹5.40 crore (cash)
- Shares: 55.34 lakh
- Price: ₹9.76 per share
- Status: Acquisition Completed
Cross-Industry Market Opportunities
Nutraceuticals: Developed 20 nutraceutical products; India market valued at USD 6.11 billion in 2024, expected to reach USD 11.55 billion by 2030 (11.39% CAGR)
Veterinary (Animal Health): India market estimated at USD 1.73 billion in 2024, projected to reach USD 4.17 billion by 2033 (10.23% CAGR)
Personal Care: India market valued at USD 28 billion in 2024, estimated to reach USD 48.3 billion by 2033 (5.60% CAGR)